Skip to Content
UW Health SMPH
Paul M. Sondel, MD, PhD close
Paul M. Sondel, MD, PhD
 

Learn More

Video icon; The Right Place: Dr. Paul Sondel Talks About American Family Children's Hospital The Right Place: Dr. Paul Sondel Talks About American Family Children's Hospital

Video; Neuroblastoma Research at UW Hospital Neuroblastoma Research at UW Hospital and Clinics

Find a Doctor Quick Search

Find a Doctor Home

For Patients

Need help selecting a doctor?
Call the Welcome Center at
(608) 821-4819 for personal assistance.

For Referring Physicians

How to refer a patient

Paul M. Sondel, MD, PhD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Paul Sondel, M.D., Ph.D. is the Reed and Carolee Walker Professor in Pediatric Oncology at the University of Wisconsin – Madison. 
 
Dr. Sondel, a Milwaukee native, completed undergraduate and graduate education at UW-Madison leading to a Ph.D. in Genetics (1975), with guidance from Bone Marrow Transplant pioneer, Fritz Bach, M.D. He received his M.D. magna cum laude in 1977 from Harvard Medical School, while beginning his research in tumor immunology. Following pediatric residency training at the Universities of Minnesota and Wisconsin, he joined the faculty of UW-Madison in 1980 in the Departments of Pediatrics, Human Oncology and Genetics. He was promoted to professor in 1987, and became leader of the UW Comprehensive Cancer Center’s Program in Immunology and Immunotherapy in 1990, when he also became Head of the Division of Pediatric Oncology.

Dr. Sondel has been a leader in scientific policy through multiple national committee roles, including The National Institutes of Health, The American Cancer Society, The Children's Oncology Group (COG), The National Cancer Institute, where he was a member of the Board of Scientific Counselors, and St. Jude's Children’s Research Hospital, where he was the Chair of their Scientific Advisory Committee and is now chair of their cancer center's external advisory board.

Clinically, he has worked with COG in contributing to the progress of the past 30 years in the development of curative treatments for childhood cancers. He is devoted to his own patients, and committed to leading a multidisciplinary team that is providing comprehensive and compassionate, state of the art treatment for all childhood cancer and hematology patients at the University of Wisconsin.

Specialties

Pediatric Hematology and Oncology

UW Health Clinics

American Family Children's Hospital
(608) 263-6420 | (800) 323-8942 | Map

Hospital Affiliation(s)

American Family Children's Hospital (primary)
Meriter Hospital, St. Mary's Hospital (secondary)

Languages Spoken

English
Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

UW School of Medicine and Public Health

Department of Pediatrics

Professional Certifications and Education

Board Certification Pediatrics
Fellowship Sidney Farber Cancer Institute, Boston, MA
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Minnesota Hospital and Clinics
Medical School Harvard Medical School, Boston, MA, 1977

Awards/Honors

Madison Magazine Top Docs 2012

Best Doctors® in America 2011

Procedures

Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.

Programs & Conditions

Research
Dr. Sondel’s research has emphasized the translation of laboratory innovations into clinical progress. His laboratory has pursued the biology of graft-versus-leukemia reactions, activation of anti-tumor immune destruction with Interleukin-2 and the use of tumor reactive monoclonal antibodies to facilitate tumor killing by lymphocytes. These studies have all moved into clinical testing led by Dr. Sondel at UW, and in national studies he has led through the Children’s Oncology Group (COG).

He has published more than 360 scientific articles and chapters, and his laboratory has provided training for 58 graduate students and post-doctoral fellows.

Learn more about Dr. Sondel's research: UW-Madison Department of Genetics | Sondel Laboratory

PubMed Articles
Yang RK Kalogriopoulos NA Rakhmilevich AL Ranheim EA Seo S Kim K Alderson KL Gan J Reisfeld RA Gillies SD Hank JA Sondel PM . Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Cancer Immunol Immunother. 2013 May 10;
[PubMed ID: 23661160]
Alderson KL Luangrath M Elsenheimer MM Gillies SD Navid F Rakhmilevich AL Sondel PM . Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG. Cancer Immunol Immunother. 2013 Apr;62(4):665-75
[PubMed ID: 23151945]
Van De Voort TJ Felder MA Yang RK Sondel PM Rakhmilevich AL . Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice. J Immunother. 2013 Jan;36(1):29-40
[PubMed ID: 23211623]
Albertini MR Hank JA Gadbaw B Kostlevy J Haldeman J Schalch H Gan J Kim K Eickhoff J Gillies SD Sondel PM . Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Cancer Immunol Immunother. 2012 Dec;61(12):2261-71
[PubMed ID: 22678096]
Rakhmilevich AL Baldeshwiler MJ Van De Voort TJ Felder MA Yang RK Kalogriopoulos NA Koslov DS Van Rooijen N Sondel PM . Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer Immunol Immunother. 2012 Oct;61(10):1683-97
[PubMed ID: 22392192]
Yang RK Kalogriopoulos NA Rakhmilevich AL Ranheim EA Seo S Kim K Alderson KL Gan J Reisfeld RA Gillies SD Hank JA Sondel PM . Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J Immunol. 2012 Sep 1;189(5):2656-64
[PubMed ID: 22844125]
Rakhmilevich AL Alderson KL Sondel PM . T-cell-independent antitumor effects of CD40 ligation. Int Rev Immunol. 2012 Aug;31(4):267-78
[PubMed ID: 22804571]
Koehn TA Trimble LL Alderson KL Erbe AK McDowell KA Grzywacz B Hank JA Sondel PM . Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Front Pharmacol. 2012;3:91
[PubMed ID: 22623917]
Russ AJ Wentworth L Xu K Rakhmilevich A Seroogy CM Sondel PM Suresh M Cho CS . Suppression of T-cell expansion by melanoma is exerted on resting cells. Ann Surg Oncol. 2011 Dec;18(13):3848-57
[PubMed ID: 21465311]
Gubbels JA Gadbaw B Buhtoiarov IN Horibata S Kapur AK Patel D Hank JA Gillies SD Sondel PM Patankar MS Connor J . Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface. Cancer Immunol Immunother. 2011 Dec;60(12):1789-800
[PubMed ID: 21792658]
Soto BL Hank JA Darjatmoko SR Polans AS Yanke EM Rakhmilevich AL Seo S Kim K Reisfeld RA Gillies SD Sondel PM . Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy. Int Immunopharmacol. 2011 Nov;11(11):1877-86
[PubMed ID: 21854876]
Soto BL Hank JA Van De Voort TJ Subramanian L Polans AS Rakhmilevich AL Yang RK Seo S Kim K Reisfeld RA Gillies SD Sondel PM . The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model. Cancer Immunol Immunother. 2011 May;60(5):731-8
[PubMed ID: 21340652]
Buhtoiarov IN Neal ZC Gan J Buhtoiarova TN Patankar MS Gubbels JA Hank JA Yamane B Rakhmilevich AL Reisfeld RA Gillies SD Sondel PM . Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting. J Leukoc Biol. 2011 Apr;89(4):625-38
[PubMed ID: 21248148]
Buhtoiarov IN Sondel PM Wigginton JM Buhtoiarova TN Yanke EM Mahvi DA Rakhmilevich AL . Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology. 2011 Feb;132(2):226-39
[PubMed ID: 21039467]
Alderson KL Sondel PM . Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol. 2011;2011:379123
[PubMed ID: 21660134]
Johnson EE Buhtoiarov IN Baldeshwiler MJ Felder MA Van Rooijen N Sondel PM Rakhmilevich AL . Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice. J Immunother. 2011 Jan;34(1):76-84
[PubMed ID: 21150715]
Delgado DC Hank JA Kolesar J Lorentzen D Gan J Seo S Kim K Shusterman S Gillies SD Reisfeld RA Yang R Gadbaw B DeSantes KB London WB Seeger RC Maris JM Sondel PM . Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010 Dec 1;70(23):9554-61
[PubMed ID: 20935224]
Hank JA Gan J Ryu H Ostendorf A Stauder MC Sternberg A Albertini M Lo KM Gillies SD Eickhoff J Sondel PM . Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. Clin Cancer Res. 2009 Sep 15;15(18):5923-30
[PubMed ID: 19737959]
Johnson EE Yamane BH Buhtoiarov IN Lum HD Rakhmilevich AL Mahvi DM Gillies SD Sondel PM . Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res. 2009 Aug 1;15(15):4875-84
[PubMed ID: 19638464]
Yamane BH Hank JA Albertini MR Sondel PM . The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin Investig Drugs. 2009 Jul;18(7):991-1000
[PubMed ID: 19548853]
Wu QL Buhtoiarov IN Sondel PM Rakhmilevich AL Ranheim EA . Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia. J Immunol. 2009 Jun 1;182(11):6771-8
[PubMed ID: 19454672]